GaBl
Scientific
Meetings2nd MENA Stakeholder Meeting on Regulatory Approval, Clinical
Settings, Interchangeability and Pharmacovigilance of Biosimilars

10 October 2018, Le Meridien Dubai, United Arab Emirates

Professor Aws Alshamsan, BPharm, RPh, PhD, Saudi Arabia

- Professor of Pharmaceutics, King Saud University, Saudi Arabia
- Dean, King Abdullah Institute for Nanotechnology, King Saud University, Saudi Arabia
- Dean (2014–2017), College of Pharmacy, King Saud University, Saudi Arabia
- Consultant, Saudi Food and Drug Authority





GaBI
Scientific
Meetings2nd MENA Stakeholder Meeting on Regulatory Approval, Clinical
Settings, Interchangeability and Pharmacovigilance of Biosimilars

10 October 2018, Le Meridien Dubai, United Arab Emirates

Biosimilars Regulatory Considerations in Saudi Arabia

Professor Aws Alshamsan, BPharm, RPh, PhD, Saudi Arabia 10 October 2018







Biosimilars Regulatory Considerations in Saudi Arabia

Aws Alshamsan, BPharm, RPh, PhD

Dean and Associate Professor at College of Pharmacy, King Saud University

Consultant of the Drug Sector at SFDA


aalshamsan@ksu.edu.sa




College of Pharmacy

BIOSIMILARS






Biological medicinal product that is highly similar to another biological medicine that has already been approved for use








Associated Risk





BIOSIMILARS




Pre-clinical assessments

- · Analytical characterisation
- Structural
- In vitro functional

- Pharmacokinetic/ pharmacodynamic (animal)
- Toxicology

Clinical assessments

- Pharmacokinetic
- Efficacy
- · Safety



Reference Product



Quality

- Drug substance
 - Manufacture
 - Characterisation
 - Control
 - Reference standard
 - Container
 - Stability
- Drug product
 - Description
 - Development
 - Manufacture
 - Control
 - Reference standard
 - Container
 - Stability

Nonclinical

- Pharmacology
 - Primary pharm.
 - Secondary pharm.
 - Safety pharm.
 - Interactions
- Pharmacokinetics
 - ADME
 - Interactions
 - Toxicology
 - Single dose
 - Repeat dose
 - Genotoxicity
 - Carcinogenicity
 - Reproduction
 - Local tolerance

Clinical

- Pharmacology
- Pharmacokinetics
 - Single dose
 - Repeat dose
 - Special populations
- Efficacy and safety
 - Dose finding
 - Schedule finding
 - Pivotal
 - Indication 1
 - Indication 2
 - Indication 3
 - Indication 4
- Post-marketing studies

Dr. Alshamsan

9


BIOSIMILARS

.

Quality

- Drug substance
- Manufacture .
- Characterisation
- Control
- Reference standard
- Container
- Stability .
- Drug product
 - Description •
 - Development
 - Manufacture .
 - Control .
 - Reference standard
 - Container
 - Stability ٠
- Comparability data
 - Analytical • comparison with reference product

Nonclinical	Clinical
 Primary pharm. Secondary pharm. Safety pharm. Interactions 	 Pharmacology Pharmacokinetics Single dose Repeat dose Special popula
Pharmacokinetics ADME Interactions 	 Efficacy and safety Dose finding Schedule finding
 Toxicology Single dose Repeat dose 	Pivotal Indication Indication



Study #2

- 1
 - Indication 3
- Indication 4
- Post-marketing studies
 - Safety in larger population
 - Efficacy in other indications
 - Immunogenicity




العتبت الصافت بتضحاه فالحقاه Saudi Food & Drug Authority


Date of publication 22/08/17 Date of implementation 22/08/17


Version 1.0


















Examples of Approved Products


- Omnitrope: Recombinant Somatropin 2014
- Remsima: Infliximab 2015
- Zarzio: Filgrastim 2015
- Grastofil: Filgrastim 2017
- Binocrit: Erythropoietin 2017
- The biosimilar on average is 37% cheaper
- Biosimilar Uptake



Examples of Rejected Products

- Follitropin alfa: Failure in Clinical comparability
- 6 Insulins: Failures in quality, safety, and efficacy


Product-Centric Evaluation <u>Saudi Food & Drug Authority</u>



SFDA

INTERCHANGEABILITY






Dr. Alshamsan


COMPLEXITY

الهيئة الصامة للضخاء والحواء Saudi Food & Drug Authority









AGGREGATION



Journal of Immunotoxicology

http://informahealthcare.com/imt ISSN: 1547-691X (print), 1547-6901 (electronic) J Immunotoxicol, 2014; 11(2): 99–109 © 2014 Informa Healthcare USA, Inc, DOI: 10.3109/1547691X.2013.821564

informa healthcare

REVIEW ARTICLE

Immunogenicity of therapeutic proteins: Influence of aggregation

Kirsty D. Ratanji, Jeremy P. Derrick, Rebecca J. Dearman, and Ian Kimber

Faculty of Life Sciences, University of Manchester, Manchester, UK

Abstract

The elicitation of anti-drug antibodies (ADA) against biotherapeutics can have detrimental effects on drug safety, efficacy, and pharmacokinetics. The immunogenicity of biotherapeutics is, therefore, an important issue. There is evidence that protein aggregation can result in enhanced immunogenicity; however, the precise immunological and biochemical mechanisms responsible are poorly defined. In the context of biotherapeutic drug development and safety assessment, understanding the mechanisms underlying aggregate immunogenicity is of considerable interest. This review provides an overview of the phenomenon of protein aggregation, the production of unwanted aggregates during bioprocessing, and how the immune response to aggregated protein differs from that provoked by non-aggregated protein. Of particular interest is the nature of the interaction of aggregates with the immune system and how subsequent ADA responses are induced. Pathways considered here include 'dassical' activation of the immune system involving antigen presenting cells and, alternatively, the breakdown of B-cell tolerance. Additionally, methods available to screen for aggregation and immunogenicity will be described. With an increased understanding of aggregationenhanced immune responses, it may be possible to develop improved manufacturing and screening processes to avoid, or at least reduce, the problems associated with ADA.


Keywords

Aggregation, anti-drug antibodies, bioprocessing, biotherapeutic, immunogenicity

History

Received 30 May 2013 Revised 26 June 2013 Accepted 28 June 2013 Published online 6 August 2013

Section 3.2.S.3 Characterization of Impurities



	الهيئة الصامة للضخاء والحواء Saudi Food & Drug Authority
Group B	Reference drug Biosimilar
Group B Substitution study (single switch)	
Group A Group B	
Biosimilars in rheumatology: current perspectives and lessons learnt. Thomas Dörner, Jonathan Kay Nat Rev Rheumatol. 2015 Dec; 11(12): 713–724	Nature Reviews Rheumatology

Dr. Alshamsan



(1) Changing <u>from an innovator drug to a biosimilar drug</u> which used that <u>same</u> <u>innovator drug as its RMP</u> for comparability (<u>or vice versa</u>) can be accepted after physician and patient discussion.

(2) Changing <u>from a biosimilar drug to another same biosimilar drug</u> from a different manufacturer can be accepted <u>after physician and patient discussion</u> only if they both used <u>the same RMP</u> for comparability purposes."

(3) Pharmacists <u>cannot substitute</u> biosimilars without [...] consultations with <u>treating physicians</u>

- Saudi Food and Drug Authority-

LEVELS



Interchangeability	 Regulator
Switching	Local authorityPrescriberPatient
Substitution	Local authorityPharmacist



Biosimilar Celebrities



